Abstract
In the recent past, several clinical trials have sought to evaluate the effectiveness of beta-blocking drugs in patients with chronic heart failure. Although the studies of certain drugs in this class yielded overwhelmingly positive results, other studies resulted in a much less clear interpretation. As result, attention has appropriately been placed on the impact of patient heterogeneity on treatment assessment. For clinical practice, it is desirable to identify subjects who would benefit from the new treatment from a risk-benefit perspective. In this paper, we investigate the results of the noted Beta-Blocker Evaluation of Survival Trial (BEST) and implement a systematic approach to achieve this goal by analyzing data available early in the study, at the time of a hypothetical initial interim analysis. We utilize multinomial outcome data from these initial patients to build a parametric score for the purpose of stratifying the remaining patients in the BEST study. We then use the data from the remaining BEST study participants to obtain a nonparametric estimate of the treatment effects, with respect to each of several ordered patient outcomes that encompass both risks and benefits of treatment, for any fixed score. Furthermore, confidence interval and band estimates are constructed to quantify the uncertainty of our inferences for the treatment differences over a range of scores. We indeed detect subsets of patients who experience significant treatment benefits in addition to other patient groups who appear to be poor candidates for treatment.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Beta-Blocker Evaluation of Survival Trial Investigators (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine 344, 1659–1667.
Bickel, P. and Rosenblatt, M. (1973). On some global measures of the deviations of density function estimates. The Annals of Statistics pages 1071–1095.
Cai, T., Tian, L., Uno, H., Solomon, S., and Wei, L. (2010). Calibrating parametric subject-specific risk estimation. Biometrika 97, 389–404.
Cai, T., Tian, L., Wong, P., and Wei, L. (2011). Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12, 270–282.
Castagno, D., Jhund, P. S., McMurray, J. J., Lewsey, J. D., Erdmann, E., Zannad, F.,... & Dargie, H. J. et al. (2010). Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European journal of heart failure, 12(6), 607–616.
Domanski, M., Krause-Steinrauf, H., Massie, B., Deedwania, P., Follmann, D., Kovar, D., Murray, D., Oren, R., Rosenberg, Y., Young, J., et al. (2003). A comparative analysis of the results from 4 trials of [beta]-blocker therapy for heart failure: Best, cibis-ii, merit-hf, and copernicus. Journal of cardiac failure 9, 354–363.
Kent, D. and Hayward, R. (2007). Limitations of applying summary results of clinical trials to individual patients. JAMA: the journal of the American Medical Association 298,1209–1212.
Li, Y., Tian, L., and Wei, L. (2011). Estimating subject-specific dependent competing risk profile with censored event time observations. Biometrics 67,427–435.
Lin, D., Wei, L., and Ying, Z. (1993). Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 80, 557–572.
Mammen, E. (1993). Bootstrap and wild bootstrap for high dimensional linear models. The Annals of Statistics 21, 255–285.
Park, Y. and Wei, L. (2003). Estimating subject-specific survival functions under the accelerated failure time model. Biometrika 90, 717–723.
Uno, H., Cai, T., Tian, L., and Wei, L. J. (2007). Evaluating prediction rules for t-year survivors with censored regression models. Journal of the American Statistical Association 102, 527–537.
Wang, R., Lagakos, S., Ware, J., Hunter, D., and Drazen, J. (2007). Statistics in medicine–reporting of subgroup analyses in clinical trials. New England Journal of Medicine 357, 2189–2194.
Wu, C. (1986). Jackknife, bootstrap and other resampling methods in regression analysis. The Annals of Statistics 14, 1261–1295.
Zheng, Y., Cai, T., and Feng, Z. (2006). Application of the time-dependent roc curves for prognostic accuracy with multiple biomarkers. Biometrics 62, 279–287.
Acknowledgments
This manuscript was prepared using BEST Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BEST investigators or the NHLBI.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this paper
Cite this paper
Claggett, B., Tian, L., Zhao, L., Castagno, D., Wei, LJ. (2013). Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Applications to Beta-Blocker Effectiveness Trials. In: Hu, M., Liu, Y., Lin, J. (eds) Topics in Applied Statistics. Springer Proceedings in Mathematics & Statistics, vol 55. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7846-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7846-1_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7845-4
Online ISBN: 978-1-4614-7846-1
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)